Q1 EPS Estimates for Journey Medical Cut by HC Wainwright

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Journey Medical to ($0.09) from ($0.05) but kept a Buy rating and a $13 price target.
• Analyst sentiment is mixed: Weiss Ratings reaffirmed a Sell (d-), while the consensus rating across analysts is a Hold with an average target of $13.
• In its latest quarter Journey Medical reported ($0.04) EPS (beating estimates) but missed revenue expectations, posted negative net margin and ROE, and its stock trades around <$strong>5.15 with a market cap of about <$strong>141M.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Equities research analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Journey Medical in a report issued on Thursday, April 23rd. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.09) for the quarter, down from their previous estimate of ($0.05). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is $0.19 per share.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Journey Medical in a report on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Journey Medical presently has an average rating of "Hold" and a consensus target price of $13.00.

Journey Medical Stock Performance

NASDAQ DERM opened at $5.15 on Monday. The firm has a market cap of $140.75 million, a price-to-earnings ratio of -10.96 and a beta of 1.03. The company has a 50 day moving average of $6.59 and a 200-day moving average of $7.48. The company has a current ratio of 1.79, a quick ratio of 1.53 and a debt-to-equity ratio of 0.79. Journey Medical has a 1-year low of $4.31 and a 1-year high of $9.56.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.02. The company had revenue of $16.08 million during the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%.

Hedge Funds Weigh In On Journey Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Salem Investment Counselors Inc. boosted its stake in Journey Medical by 18.2% in the fourth quarter. Salem Investment Counselors Inc. now owns 14,300 shares of the company's stock valued at $110,000 after acquiring an additional 2,200 shares during the last quarter. Occudo Quantitative Strategies LP boosted its stake in Journey Medical by 22.3% in the fourth quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company's stock valued at $146,000 after acquiring an additional 3,443 shares during the last quarter. Opaleye Management Inc. boosted its stake in Journey Medical by 0.4% in the fourth quarter. Opaleye Management Inc. now owns 975,000 shares of the company's stock valued at $7,517,000 after acquiring an additional 3,936 shares during the last quarter. Bank of America Corp DE boosted its stake in Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after acquiring an additional 4,048 shares during the last quarter. Finally, Barclays PLC boosted its stake in Journey Medical by 28.2% in the fourth quarter. Barclays PLC now owns 22,521 shares of the company's stock valued at $174,000 after acquiring an additional 4,955 shares during the last quarter. 7.25% of the stock is owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.